Deucravacitinib in Psoriatic Disease
Show notes
In this episode of Inside GRAPPA, Dr. Andre Lucas Ribeiro, Dr. Anna López Ferrer, and Professor Philip J. Mease explore the role of deucravacitinib, a selective TYK2 inhibitor, in the evolving treatment landscape of psoriatic disease.
Together, they examine the unmet needs in psoriasis and psoriatic arthritis, discuss the clinical evidence supporting deucravacitinib's efficacy and safety, and consider its potential place among existing treatment options. The conversation also highlights the importance of individualized treatment decisions, remaining evidence gaps, and future research opportunities.
- Explore ongoing unmet needs in psoriatic arthritis and the importance of expanding oral treatment options.
- Understand deucravacitinib's unique mechanism of action and how selective TYK2 inhibition differs from traditional JAK inhibitors.
- Review key findings from the POETYK clinical trials, including efficacy in joint and skin manifestations.
- Examine the safety and tolerability profile, including insights from long-term psoriasis data.
- Discuss how deucravacitinib may fit into clinical practice and which patient characteristics may influence treatment selection.
- Identify remaining research questions, including axial disease, difficult-to-treat PsA, and combination therapies.
- Look ahead to ongoing studies and future opportunities to advance personalized treatment in psoriatic disease.
Stay up to date with the latest psoriatic disease research, GRAPPA initiatives, and future episodes of Inside GRAPPA at grappanetwork.org.
Hosted on Acast. See acast.com/privacy for more information.